000294555 001__ 294555
000294555 005__ 20250520140612.0
000294555 0247_ $$2doi$$a10.1093/neuonc/noae239
000294555 0247_ $$2pmid$$apmid:39535060
000294555 0247_ $$2ISSN$$a1522-8517
000294555 0247_ $$2ISSN$$a1523-5866
000294555 0247_ $$2altmetric$$aaltmetric:170398627
000294555 037__ $$aDKFZ-2024-02330
000294555 041__ $$aEnglish
000294555 082__ $$a610
000294555 1001_ $$0P:(DE-He78)f83dff4ca396c46c049f1808e2f84000$$aBerghaus, Natalie$$b0$$eFirst author$$udkfz
000294555 245__ $$aMeningiomas: Sex-Specific Differences and Prognostic Implications of a Chromosome X Loss.
000294555 260__ $$aOxford$$bOxford Univ. Press$$c2025
000294555 3367_ $$2DRIVER$$aarticle
000294555 3367_ $$2DataCite$$aOutput Types/Journal article
000294555 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1747742734_3487
000294555 3367_ $$2BibTeX$$aARTICLE
000294555 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294555 3367_ $$00$$2EndNote$$aJournal Article
000294555 500__ $$a#EA:B300#LA:B300# / 2025 May 15;27(4):1019-1028
000294555 520__ $$aMeningiomas are the most common primary intracranial tumours in adults. Several studies proposed new stratification systems with a more accurate risk prediction than the WHO grading, e.g. based on methylation and copy number variations (CNVs). Yet, common shortcomings in these analyses are either a lack of stratification by sex of patients or excluding the gonososmes from CNV assessment.Within this study, DNA methylation array data from 7,424 meningioma samples as well as targeted sequencing, clinical annotations and morphology subtyping of 796 samples were examined for differences between females and males regarding mutations, methylation classes, copy number variations and histology.Meningiomas from females accounted for about 53 % of the malignant tumours and present a loss of one X chromosome in 57 % of these malignant cases. In the group of benign tumours, females comprised about 75 % of the patients. Therein, a loss of one X chromosome was detected in only about 10 % of the cases but was associated with a significantly worse progression free survival.Although genomic instability is a common feature of malignant meningiomas, particularly loss of the X chromosome in tumours of female patients in otherwise histologically and molecularly low-risk tumours confers higher risk. Hence, the gonosomal copy number status can be leveraged for increased diagnostic accuracy.
000294555 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000294555 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294555 650_7 $$2Other$$aCopy Number Variations
000294555 650_7 $$2Other$$aMeningioma
000294555 650_7 $$2Other$$aX chromosome
000294555 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000294555 7001_ $$0P:(DE-He78)335b04cc04673d0893cb2572e920fe17$$aSavran, Dilan$$b2$$udkfz
000294555 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b3$$udkfz
000294555 7001_ $$aMaas, Sybren L N$$b4
000294555 7001_ $$aPreusser, Matthias$$b5
000294555 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b6
000294555 7001_ $$aAcker, Till$$b7
000294555 7001_ $$aHerold-Mende, Christel$$b8
000294555 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b9$$udkfz
000294555 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b10$$udkfz
000294555 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b11$$eLast author$$udkfz
000294555 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae239$$gp. noae239$$n4$$p1019-1028$$tNeuro-Oncology$$v27$$x1522-8517$$y2025
000294555 909CO $$ooai:inrepo02.dkfz.de:294555$$pVDB
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f83dff4ca396c46c049f1808e2f84000$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)335b04cc04673d0893cb2572e920fe17$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000294555 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000294555 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000294555 9141_ $$y2024
000294555 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000294555 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000294555 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000294555 9202_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000294555 9201_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000294555 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000294555 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x2
000294555 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000294555 9200_ $$0I:(DE-He78)B300-20160331$$kB300$$lKKE Neuropathologie$$x0
000294555 980__ $$ajournal
000294555 980__ $$aVDB
000294555 980__ $$aI:(DE-He78)B300-20160331
000294555 980__ $$aI:(DE-He78)C060-20160331
000294555 980__ $$aI:(DE-He78)B320-20160331
000294555 980__ $$aI:(DE-He78)HD01-20160331
000294555 980__ $$aUNRESTRICTED